Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thai Decision On Revised CL Policy To Be Ready By April

This article was originally published in PharmAsia News

Executive Summary

While debate continues over Thailand's decision to continue its compulsory licensing practice, the Health Ministry expects a final decision to be ready by April. Minister Chaiya Sasomsap, who stirred the controversy by saying the CL policy of the previous administration would continue in place during a policy review, asked for a two-week extension of the deadline in light of the continuing international conflict over the practice. Four cancer drugs by foreign drug makers are at the core of the CL policy. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts